Trophos SA, a biopharmaceutical company specializing in the discovery and development of drugs for neurological disorders, announced today that the first patients with NonAlcoholic SteatoHepatitis (NASH) have been enrolled in an exploratory Phase IIa clinical trial of its lead product, TRO19622. It is the first study investigating the potential benefits of TRO19622 beyond neurological conditions.

More: continued here

This entry was posted on Thursday, May 22nd, 2008 at 8:05 am and is filed under Liver Disease / Hepatitis. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.